|
1）Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012; 44: 760-4
|
|
|
|
2）Totoki Y, Tatsuno K, Yamamoto S, et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet. 2011; 43: 464-9
|
|
|
|
|
|
3）Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012; 44: 694-8
|
|
|
|
|
|
4）Huang J，Deng Q，Wang Q，et al. Exome sequencing of hepatitis B virus associated hepatocellular carcinoma. Nat Genet. 2012; 44: 1117-21
|
|
|
|
|
|
5）Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013; 4: 2218
|
|
|
|
|
|
6）Shibata T, Aburatani H. Exploration of liver cancer genomes．Nat Rev Gastroenterol Hepatol. 2014; 11: 340-9
|
|
|
|
|
|
7）Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014; 46: 1267-73
|
|
|
|
|
|
8）Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015; 47: 505-11
|
|
|
|
|
|
9）Honeyman JN，Simon EP，Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014; 343: 1010-4
|
|
|
|
|
|
10）Matsumoto T, Shimizu T, Nishijima N, et al. Hepatic inflammation facilitates transcription-associated mutagenesis via AID activity and enhances liver tumorigenesis. Carcinogenesis. 2015; 36: 904-13
|
|
|
|
|
|
11）Kim SK, Nasu A, Komori J, et al. A model of liver carcinogenesis originating from hepatic progenitor cells with accumulation of genetic alterations. Int J Cancer. 2014; 134: 1067-76
|
|
|
|
|
|
12）Ikeda A, Shimizu T, Matsumoto Y, et al. Leptin Receptor Somatic Mutations Are Frequent in HCV-Infected Cirrhotic Liver and Associated With Hepatocellular Carcinoma. Gastroenterology. 2014; 146: 222-32
|
|
|
|
|
|
13）Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405-16
|
|
|
|
|
|
14） Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014; 59: 2083-91
|
|
|
|
|
|
15）Kim SK, Marusawa H, Eso Y, et al. Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion. 2011; 84 Suppl 1: 43-9
|
|
|
|
|
|
16）Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014; 20: 2072-9
|
|
|
|
|
|
17）Hollebecque A, Malka D, Ferté C, et al. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons. Eur J Cancer. 2015; 51: 327-39
|
|
|
|
|
|
18）Shen H, Zhong F, Zhang Y, et al. Ranscriptome and proteome of human hepatocellular carcinoma reveal shared metastatic pathways with significant genes. Proteomics. 2015; 15: 1793-800
|
|
|
|
|
|
19）Miao R, Luo H, Zhou H, et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol. 2014; 61: 840-9
|
|
|
|
|
|
20）Takeda H, Takai A, Marusawa H. Comprehensive characterization of hepatitis B virus-associated multifocal hepatocellular carcinoma using a multi-omics strategy. Ann Transl Med. 2015; 3: 3
|
|
|
|
|
|
21）Bupathi M, Kaseb A, Meric-Bernstam F, et al. Hepatocellular carcinoma: Where there is unmet need. Mol Oncol. 2015; 9: 1501-9
|
|
|
|
|
|
22）Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015; 33: 172-9
|
|
|
|
|
|
23）Johnson PJ, Qin S, Park JW. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013; 31: 3517-24
|
|
|
|
|
|
24）Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645-52
|
|
|
|
|
|
25）Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012; 44: 765-9
|
|
|
|
|
|
26）Fujimoto A, Furuta M, Shiraishi Y, et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun. 2015; 6: 6120
|
|
|
|
|
|
27）Cornella H, Alsinet C, Sayols S, et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology. 2015; 148: 806-18
|
|
|
|
|
|
28）Leedham SJ, Graham TA, Oukrif D, et al. Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology. 2009; 136: 542-50
|
|
|
|
|
|
29）Morita S, Matsumoto Y, Okuyama S, et al. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrettʼs oesophageal adenocarcinoma. Carcinogenesis. 2011; 32: 1706-12
|
|
|
|
|
|
30）Shimizu T, Marusawa H, Matsumoto Y, et al. Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection. Gastroenterology. 2014; 147: 407-17
|
|
|
|
|